{"id":"https://openalex.org/W4415939725","doi":"https://doi.org/10.1016/j.annonc.2025.08.1871","title":"1238eTiP Phase I/IIa, open-label, dose finding, safety and exploratory trial of THEO-260: A novel oncolytic immunotherapy, by intravenous delivery in patients with high grade serous or endometrioid ovarian cancer","display_name":"1238eTiP Phase I/IIa, open-label, dose finding, safety and exploratory trial of THEO-260: A novel oncolytic immunotherapy, by intravenous delivery in patients with high grade serous or endometrioid ovarian cancer","publication_year":2025,"publication_date":"2025-09-01","ids":{"openalex":"https://openalex.org/W4415939725","doi":"https://doi.org/10.1016/j.annonc.2025.08.1871"},"language":"en","primary_location":{"id":"doi:10.1016/j.annonc.2025.08.1871","doi":"https://doi.org/10.1016/j.annonc.2025.08.1871","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2025.08.1871","pdf_url":null,"source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://doi.org/10.1016/j.annonc.2025.08.1871","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028432965","display_name":"Matilde Saggese","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102438","display_name":"Theolytics (United Kingdom)","ror":"https://ror.org/012y0eh02","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102438"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M. Saggese","raw_affiliation_strings":["Theolytics Ltd, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Theolytics Ltd, Oxford, United Kingdom","institution_ids":["https://openalex.org/I4210102438"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011199516","display_name":"P. Roxburgh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"P. Roxburgh","raw_affiliation_strings":["Beatson West of Scotland Cancer Centre, Beatson West of Scotland, Glasgow, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson West of Scotland Cancer Centre, Beatson West of Scotland, Glasgow, United Kingdom","institution_ids":["https://openalex.org/I2800373718"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035813994","display_name":"Douglas Cartwright","orcid":"https://orcid.org/0000-0002-8780-6765","observed_orcids":["https://orcid.org/0000-0002-8780-6765"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D. Cartwright","raw_affiliation_strings":["Beatson West of Scotland Cancer Centre, Beatson West of Scotland, Glasgow, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson West of Scotland Cancer Centre, Beatson West of Scotland, Glasgow, United Kingdom","institution_ids":["https://openalex.org/I2800373718"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091681745","display_name":"Mark Peter Lythgoe","orcid":"https://orcid.org/0000-0002-8952-7639","observed_orcids":["https://orcid.org/0000-0002-8952-7639"]},"institutions":[{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M. Lythgoe","raw_affiliation_strings":["Department of Surgery and Cancer, Imperial College London, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Surgery and Cancer, Imperial College London, London, United Kingdom","institution_ids":["https://openalex.org/I47508984"]}]},{"author_position":"middle","author":{"id":null,"display_name":"M. Zameer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M. Zameer","raw_affiliation_strings":["Department of Oncology, University of Oxford, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, University of Oxford, Oxford, United Kingdom","institution_ids":["https://openalex.org/I40120149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023223057","display_name":"Miriam Baz\u00e1n\u2010Peregrino","orcid":"https://orcid.org/0000-0001-7367-8304","observed_orcids":["https://orcid.org/0000-0001-7367-8304"]},"institutions":[{"id":"https://openalex.org/I4210102438","display_name":"Theolytics (United Kingdom)","ror":"https://ror.org/012y0eh02","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102438"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M. Bazan Peregrino","raw_affiliation_strings":["Theolytics Ltd, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Theolytics Ltd, Oxford, United Kingdom","institution_ids":["https://openalex.org/I4210102438"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5093099128","display_name":"R. Ackerman-Johnson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102438","display_name":"Theolytics (United Kingdom)","ror":"https://ror.org/012y0eh02","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102438"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"R. Ackerman-Johnson","raw_affiliation_strings":["Theolytics Ltd, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Theolytics Ltd, Oxford, United Kingdom","institution_ids":["https://openalex.org/I4210102438"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003602019","display_name":"Rakesh Dattani","orcid":"https://orcid.org/0000-0002-1257-1017","observed_orcids":["https://orcid.org/0000-0002-1257-1017"]},"institutions":[{"id":"https://openalex.org/I4210102438","display_name":"Theolytics (United Kingdom)","ror":"https://ror.org/012y0eh02","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102438"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"R. Dattani","raw_affiliation_strings":["Theolytics Ltd, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Theolytics Ltd, Oxford, United Kingdom","institution_ids":["https://openalex.org/I4210102438"]}]},{"author_position":"middle","author":{"id":null,"display_name":"A. Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102438","display_name":"Theolytics (United Kingdom)","ror":"https://ror.org/012y0eh02","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102438"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A. Smith","raw_affiliation_strings":["Theolytics Ltd, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Theolytics Ltd, Oxford, United Kingdom","institution_ids":["https://openalex.org/I4210102438"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110163812","display_name":"K. Fisher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102438","display_name":"Theolytics (United Kingdom)","ror":"https://ror.org/012y0eh02","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102438"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"K. Fisher","raw_affiliation_strings":["Theolytics Ltd, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Theolytics Ltd, Oxford, United Kingdom","institution_ids":["https://openalex.org/I4210102438"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002738508","display_name":"David Apelian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102438","display_name":"Theolytics (United Kingdom)","ror":"https://ror.org/012y0eh02","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102438"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D. Apelian","raw_affiliation_strings":["Theolytics Ltd, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Theolytics Ltd, Oxford, United Kingdom","institution_ids":["https://openalex.org/I4210102438"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068550336","display_name":"Sarah Patricia Blagden","orcid":"https://orcid.org/0000-0001-8783-3491","observed_orcids":["https://orcid.org/0000-0001-8783-3491"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S. Blagden","raw_affiliation_strings":["Department of Oncology, University of Oxford, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, University of Oxford, Oxford, United Kingdom","institution_ids":["https://openalex.org/I40120149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054919051","display_name":"Matilda Duffy","orcid":"https://orcid.org/0000-0002-4225-9163","observed_orcids":["https://orcid.org/0000-0002-4225-9163"]},"institutions":[{"id":"https://openalex.org/I4210102438","display_name":"Theolytics (United Kingdom)","ror":"https://ror.org/012y0eh02","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210102438"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M. Duffy","raw_affiliation_strings":["Theolytics Ltd, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Theolytics Ltd, Oxford, United Kingdom","institution_ids":["https://openalex.org/I4210102438"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5007279195","display_name":"Jonathan Krell","orcid":"https://orcid.org/0000-0002-9835-9227","observed_orcids":["https://orcid.org/0000-0002-9835-9227"]},"institutions":[{"id":"https://openalex.org/I47508984","display_name":"Imperial College London","ror":"https://ror.org/041kmwe10","country_code":"GB","type":"education","lineage":["https://openalex.org/I47508984"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. Krell","raw_affiliation_strings":["Department of Surgery and Cancer, Imperial College London, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Surgery and Cancer, Imperial College London, London, United Kingdom","institution_ids":["https://openalex.org/I47508984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5080,"currency":"USD","value_usd":5080},"apc_paid":null,"fwci":0.3919,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.52902487,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":91,"max":95},"biblio":{"volume":"36","issue":null,"first_page":"S747","last_page":"S747"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.7681000232696533,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.7681000232696533,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.17479999363422394,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.013199999928474426,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oncolytic-immunotherapy","display_name":"oncolytic immunotherapy","score":0.875},{"id":"https://openalex.org/keywords/high-grade-serous-ovarian-carcinoma","display_name":"high-grade serous ovarian cancer","score":0.9020000100135803},{"id":"https://openalex.org/keywords/endometrioid-ovarian-carcinoma","display_name":"endometrioid ovarian cancer","score":1.0},{"id":"https://openalex.org/keywords/platinum-resistant-ovarian-cancer","display_name":"platinum-resistant ovarian cancer","score":0.7950000166893005},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.8889999985694885},{"id":"https://openalex.org/keywords/cancer-associated-fibroblasts","display_name":"cancer-associated fibroblasts","score":0.9430000185966492},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.9110000133514404},{"id":"https://openalex.org/keywords/intravenous-delivery","display_name":"intravenous delivery","score":0.8349999785423279},{"id":"https://openalex.org/keywords/dose-finding","display_name":"dose-finding","score":0.6150000095367432},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.6140000224113464}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9460999965667725},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6891999840736389},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6021000146865845},{"id":"https://openalex.org/C150173356","wikidata":"https://www.wikidata.org/wiki/Q6144101","display_name":"Serous fluid","level":2,"score":0.5971999764442444},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.5318999886512756},{"id":"https://openalex.org/C16930146","wikidata":"https://www.wikidata.org/wiki/Q4381253","display_name":"Stromal cell","level":2,"score":0.49959999322891235},{"id":"https://openalex.org/C2993684365","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Serous ovarian cancer","level":4,"score":0.4957999885082245},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.4677000045776367},{"id":"https://openalex.org/C82210918","wikidata":"https://www.wikidata.org/wiki/Q1560099","display_name":"Oncolytic virus","level":3,"score":0.46149998903274536},{"id":"https://openalex.org/C2992773878","wikidata":"https://www.wikidata.org/wiki/Q7645976","display_name":"Epithelial ovarian cancer","level":4,"score":0.44530001282691956},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4318000078201294},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.4246000051498413},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.3716999888420105},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.35100001096725464},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.34049999713897705},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2985000014305115},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.2921999990940094},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.2921999990940094},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.2797999978065491},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.2721000015735626},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.2709999978542328},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.2556999921798706}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.annonc.2025.08.1871","doi":"https://doi.org/10.1016/j.annonc.2025.08.1871","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2025.08.1871","pdf_url":null,"source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.annonc.2025.08.1871","doi":"https://doi.org/10.1016/j.annonc.2025.08.1871","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2025.08.1871","pdf_url":null,"source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7162641480","https://openalex.org/W4387812664","https://openalex.org/W4415871433","https://openalex.org/W4372052838","https://openalex.org/W3096600782","https://openalex.org/W4408137176","https://openalex.org/W4285792280","https://openalex.org/W2001076864","https://openalex.org/W1967286830","https://openalex.org/W4306945841"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-11-06T00:00:00"}